Company Overview - NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [3] - The company is developing DA-1726 for obesity treatment and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [3] Product Development - DA-1726 is a novel oxyntomodulin (OXM) analogue that acts as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), potentially leading to superior weight loss compared to selective GLP1R agonists [3] - DA-1241 is a G-protein-coupled receptor 119 (GPR119) agonist that enhances the release of gut peptides GLP-1, GIP, and PYY, showing positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism in preclinical studies [3] Upcoming Events - NeuroBo management will present a company overview at the Emerging Growth Conference on July 18, 2024, at 10:50 am ET [1] - Following the presentation, there will be a Q&A session where questions can be submitted in advance [2][6]
NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July